Teleflex Incorporated (NYSE:TFX) Receives Consensus Rating of “Hold” from Analysts

Shares of Teleflex Incorporated (NYSE:TFX) have received an average recommendation of “Hold” from the eleven analysts that are currently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, eight have issued a hold recommendation and two have assigned a buy recommendation to the company. The average 12-month price target among analysts that have covered the stock in the last year is $164.63.

A number of research analysts have weighed in on TFX shares. Truist Financial reduced their target price on Teleflex from $140.00 to $137.00 and set a “hold” rating for the company in a report on Monday, May 5th. Bank of America lowered Teleflex from a “neutral” rating to an “underperform” rating and cut their price objective for the stock from $235.00 to $140.00 in a report on Tuesday, March 4th. Wall Street Zen lowered Teleflex from a “buy” rating to a “hold” rating in a report on Friday, February 28th. Needham & Company LLC reissued a “hold” rating on shares of Teleflex in a report on Wednesday, March 12th. Finally, Citizens Jmp lowered Teleflex from an “outperform” rating to a “market perform” rating in a report on Thursday, February 27th.

Institutional Trading of Teleflex

A number of hedge funds have recently bought and sold shares of TFX. Empowered Funds LLC bought a new stake in Teleflex in the 4th quarter worth approximately $259,000. Asset Management One Co. Ltd. lifted its position in Teleflex by 15.6% in the fourth quarter. Asset Management One Co. Ltd. now owns 19,233 shares of the medical technology company’s stock valued at $3,453,000 after purchasing an additional 2,589 shares during the last quarter. Vontobel Holding Ltd. lifted its position in Teleflex by 21.9% in the fourth quarter. Vontobel Holding Ltd. now owns 1,393 shares of the medical technology company’s stock valued at $248,000 after purchasing an additional 250 shares during the last quarter. Sanctuary Advisors LLC lifted its position in Teleflex by 28.2% in the fourth quarter. Sanctuary Advisors LLC now owns 6,251 shares of the medical technology company’s stock valued at $1,143,000 after purchasing an additional 1,374 shares during the last quarter. Finally, Alberta Investment Management Corp bought a new stake in Teleflex in the fourth quarter valued at approximately $2,011,000. Institutional investors own 95.62% of the company’s stock.

Teleflex Stock Down 2.9%

TFX stock opened at $117.55 on Wednesday. The company has a quick ratio of 1.32, a current ratio of 2.28 and a debt-to-equity ratio of 0.44. The firm has a market capitalization of $5.19 billion, a PE ratio of 37.08, a PEG ratio of 1.90 and a beta of 1.10. Teleflex has a twelve month low of $117.24 and a twelve month high of $249.91. The stock has a 50-day simple moving average of $126.25 and a two-hundred day simple moving average of $151.38.

Teleflex (NYSE:TFX) last posted its earnings results on Thursday, May 1st. The medical technology company reported $2.91 earnings per share for the quarter, beating analysts’ consensus estimates of $2.88 by $0.03. The business had revenue of $700.67 million during the quarter, compared to analyst estimates of $699.37 million. Teleflex had a return on equity of 14.73% and a net margin of 4.96%. The company’s quarterly revenue was down 5.0% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $3.21 EPS. On average, equities analysts predict that Teleflex will post 13.98 EPS for the current fiscal year.

Teleflex Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, June 16th. Investors of record on Tuesday, May 20th were given a $0.34 dividend. The ex-dividend date of this dividend was Tuesday, May 20th. This represents a $1.36 dividend on an annualized basis and a yield of 1.16%. Teleflex’s payout ratio is 42.90%.

Teleflex Company Profile

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.